Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets

Ashai, N; Swain, SM

Ashai, N (通讯作者),Georgetown Lombardi Comprehens Canc Ctr & MedStar, Dept Med, Washington, DC 20007 USA.

CANCERS, 2023; 15 (6):

Abstract

Simple Summary CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are the established first-line treatment for metastatic and advanced hormone recepto......

Full Text Link